| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended rele...
-SEC Filing
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and ann...
Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to ...
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday...